Next step in incretin therapy: from single to dual agonism

Thursday, 30 September 2021, 10:00 - 11:30, Athens Hall

Chair: J.J. Meier, DE

M.J. Davies, UK: Introduction to the molecule

T. Heise, DE: Tirzepatide mechanism of action: effects on endocrine function and insulin resistance in patients with type 2 diabetes

T. Battelino, SI: Effect of tirzepatide on glycaemic control captured with continuous glucose monitoring in patients with type 2 diabetes (SURPASS-3 CGM)

K. Cusi, US: The effects of tirzepatide on liver fat content and abdominal adipose tissue in patients with type 2 diabetes (SURPASS-3 MRI)

S. Del Prato, IT: SURPASS 4: Efficacy and safety of tirzepatide once weekly versus insulin glargine in patients with type 2 diabetes and increased cardiovascular risk

J.W. Eriksson, SE: Commentary 

Q&A with Speakers and Closing remarks by the Chair